Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma

Trial Profile

Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2013

At a glance

  • Drugs Benzylguanine (Primary) ; Carmustine (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Most Recent Events

    • 10 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Actual number of patients (21) added as reported by ClinicalTrials.gov record.
    • 02 Mar 2010 Actual end date (1 Jul 2007) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top